Dicerna Pharmaceuticals, a US-based biopharmaceutical company which is developing RNA interference (RNAi)-based therapeutics, has closed a $60m series C financing.  The round was led by new investor, private investment bank RA Capital, with the participation of new investors, investments firms Brookside Capital, Deerfield, and Omega Funds.  All of Dicerna’s existing institutional investors also particpated: Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One, the corporate venture capital arm of pharmaceutical company GlaxoSmithKline (GSK).

Previously, Dicerna raised $25m series B financing in August 2010, and $13m series A financing in November 2007.

Proceeds from the series C financing will be used to advance two or more programs into the clinic and to progress other preclinical programs. The company also plans to use the proceeds to continue to develop innovative drug delivery systems, which combine Dicerna’s DsiRNA molecules with targeting moieties allowing for direct delivery into specific cells of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?